Axsome Therapeutics Stock Today
AXSM Stock | USD 71.17 1.91 2.61% |
Performance0 of 100
| Odds Of DistressLess than 11
|
Axsome Therapeutics is selling at 71.17 as of the 25th of April 2024; that is -2.61 percent decrease since the beginning of the trading day. The stock's lowest day price was 70.3. Axsome Therapeutics has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Axsome Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of November 2015 | Category Healthcare | Classification Health Care |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 47.37 M outstanding shares of which 7.65 M shares are presently shorted by private and institutional investors with about 8.86 trading days to cover. More on Axsome Therapeutics
Moving against Axsome Stock
0.76 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
0.75 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
0.7 | NRSNW | NeuroSense Therapeutics | PairCorr |
0.56 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
0.54 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
0.49 | BMY | Bristol Myers Squibb Earnings Call Today | PairCorr |
0.48 | ELYM | Eliem Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 13th of May 2024
Axsome Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Axsome Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Axsome Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Chairman of the Board, CEO | Herriot Tabuteau | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation Analysts covering Axsome Therapeutics report their recommendations after researching Axsome Therapeutics' financial statements, talking to executives and customers, or listening in on Axsome Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Axsome Therapeutics. The Axsome consensus assessment is calculated by taking the average forecast from all of the analysts covering Axsome Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength Based on the key indicators related to Axsome Therapeutics' liquidity, profitability, solvency, and operating efficiency, Axsome Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Axsome Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Axsome Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Axsome Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Axsome Therapeutics' financial leverage. It provides some insight into what part of Axsome Therapeutics' total assets is financed by creditors.
|
Axsome Therapeutics (AXSM) is traded on NASDAQ Exchange in USA. It is located in One World Trade Center, New York, NY, United States, 10007 and employs 545 people. Axsome Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.41 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Axsome Therapeutics's market, we take the total number of its shares issued and multiply it by Axsome Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Axsome Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 47.37 M outstanding shares of which 7.65 M shares are presently shorted by private and institutional investors with about 8.86 trading days to cover.
Axsome Therapeutics currently holds about 73.39 M in cash with (145.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Check Axsome Therapeutics Probability Of Bankruptcy
Ownership AllocationAxsome Therapeutics holds a total of 47.37 Million outstanding shares. The majority of Axsome Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Axsome Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Axsome Therapeutics. Please pay attention to any change in the institutional holdings of Axsome Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that nearly four hundred seventy-three thousand seven hundred fourty-four invesors are currently shorting Axsome Therapeutics expressing very little confidence in its future performance.
Check Axsome Ownership Details
Axsome Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Axsome Therapeutics jumping above the current price in 90 days from now is about 84.63%. The Axsome Therapeutics probability density function shows the probability of Axsome Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.0585. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Axsome Therapeutics will likely underperform. Additionally, axsome Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Axsome Therapeutics to move above the current price in 90 days from now is about 84.63 (This Axsome Therapeutics probability density function shows the probability of Axsome Stock to fall within a particular range of prices over 90 days) .
Axsome Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Axsome Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Axsome Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Axsome Therapeutics' value.Instituion | Recorded On | Shares | |
Fmr Inc | 2023-12-31 | 882 K | |
Geode Capital Management, Llc | 2023-12-31 | 822.3 K | |
Alethea Capital Management, Llc | 2023-12-31 | 752 K | |
Pictet Asset Manangement Sa | 2023-12-31 | 698.9 K | |
Bellevue Group Ag | 2023-12-31 | 635.4 K | |
Morgan Stanley - Brokerage Accounts | 2023-12-31 | 619.4 K | |
Jefferies Financial Group Inc | 2023-12-31 | 563.3 K | |
Woodline Partners Lp | 2023-12-31 | 562.2 K | |
Point72 Asset Management, L.p. | 2023-09-30 | 531.9 K | |
Rtw Investments, Llc | 2023-12-31 | 4.5 M | |
Vanguard Group Inc | 2023-12-31 | 3.7 M |
Axsome Therapeutics Historical Income Statement
Axsome Therapeutics Income Statement is one of the three primary financial statements used for reporting Axsome's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Axsome Therapeutics revenue and expense. Axsome Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Axsome Therapeutics' Total Revenue is very stable compared to the past year. As of the 25th of April 2024, Gross Profit is likely to grow to about 249.6 M, though EBIT is likely to grow to (173.8 M). View More FundamentalsAxsome Stock Against Markets
Picking the right benchmark for Axsome Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Axsome Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Axsome Therapeutics is critical whether you are bullish or bearish towards Axsome Therapeutics at a given time. Please also check how Axsome Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Axsome Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
All Next | Launch Module |
Axsome Therapeutics Corporate Directors
Axsome Therapeutics corporate directors refer to members of an Axsome Therapeutics board of directors. The board of directors generally takes responsibility for the Axsome Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Axsome Therapeutics' board members must vote for the resolution. The Axsome Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.Joseph DebrahAffu | Director of Finance, Interim Principal Accounting Officer | Profile | |
Mark Saad | Independent Director | Profile | |
Roger Jeffs | Independent Director | Profile | |
Mark Coleman | Independent Director | Profile |
How to buy Axsome Stock?
Before investing in Axsome Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Axsome Therapeutics. To buy Axsome Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Axsome Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Axsome Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Axsome Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Axsome Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Axsome Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Axsome Stock please use our How to Invest in Axsome Therapeutics guide.
Already Invested in Axsome Therapeutics?
The danger of trading Axsome Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Axsome Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Axsome Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Axsome Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Axsome Stock analysis
When running Axsome Therapeutics' price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.27) | Revenue Per Share 5.957 | Quarterly Revenue Growth 1.935 | Return On Assets (0.25) | Return On Equity (1.59) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.